The stock of TrovaGene Inc (NASDAQ:TROV) is a huge mover today! About 395,368 shares traded hands or 45.51% up from the average. TrovaGene Inc (NASDAQ:TROV) has declined 30.29% since April 28, 2016 and is downtrending. It has underperformed by 36.21% the S&P500.
The move comes after 6 months negative chart setup for the $79.00 million company. It was reported on Dec, 1 by Barchart.com. We have $2.52 PT which if reached, will make NASDAQ:TROV worth $3.16M less.
Analysts await TrovaGene Inc (NASDAQ:TROV) to report earnings on March, 9. They expect $-0.32 earnings per share, down 18.52% or $0.05 from last year’s $-0.27 per share. After $-0.34 actual earnings per share reported by TrovaGene Inc for the previous quarter, Wall Street now forecasts -5.88% EPS growth.
TrovaGene Inc (NASDAQ:TROV) Ratings Coverage
Out of 5 analysts covering TrovaGene (NASDAQ:TROV), 0 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. TrovaGene has been the topic of 8 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The rating was maintained by Avondale on Tuesday, March 29 with “Market Perform”. Cantor Fitzgerald downgraded the stock to “Hold” rating in Monday, April 25 report. The firm earned “Sector Perform” rating on Tuesday, April 26 by Leerink Swann. The firm has “Outperform” rating by Leerink Swann given on Friday, August 14. The rating was downgraded by Piper Jaffray on Monday, April 25 to “Neutral”. On Friday, March 11 the stock rating was downgraded by Janney Capital to “Neutral”. Cantor Fitzgerald initiated it with “Buy” rating and $10 target price in Tuesday, September 15 report.
According to Zacks Investment Research, “Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism.”
Insitutional Activity: The institutional sentiment increased to 1.29 in 2016 Q2. Its up 0.48, from 0.81 in 2016Q1. The ratio is positive, as 8 funds sold all TrovaGene Inc shares owned while 23 reduced positions. 14 funds bought stakes while 11 increased positions. They now own 9.19 million shares or 9.18% less from 10.12 million shares in 2016Q1.
Schwab Charles Inc has 35,347 shares for 0% of their US portfolio. Gp holds 0% of its portfolio in TrovaGene Inc (NASDAQ:TROV) for 16,218 shares. Lba Wealth Llc accumulated 5,000 shares or 0.01% of the stock. Creative Planning accumulated 9,700 shares or 0% of the stock. Spot Trading Ltd Liability Corp holds 6,865 shares or 0% of its portfolio. Tiaa Cref Inv Ltd Limited Liability Company holds 138,968 shares or 0% of its portfolio. California Pub Employees Retirement holds 77,200 shares or 0% of its portfolio. Moreover, Deutsche National Bank & Trust Ag has 0% invested in TrovaGene Inc (NASDAQ:TROV) for 11,661 shares. Teachers Advisors Inc holds 48,120 shares or 0% of its portfolio. Moreover, Blackrock Mgmt has 0% invested in TrovaGene Inc (NASDAQ:TROV) for 113,232 shares. Northern Trust has 309,754 shares for 0% of their US portfolio. California State Teachers Retirement System accumulated 59,077 shares or 0% of the stock. Tci Wealth Inc reported 2,100 shares or 0.01% of all its holdings. Blackrock last reported 2,200 shares in the company. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock.
More news for TrovaGene Inc (NASDAQ:TROV) were recently published by: Streetinsider.com, which released: “Form 8-K Trovagene, Inc. For: Nov 30” on November 30, 2016. Prnewswire.com‘s article titled: “Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments” and published on November 09, 2016 is yet another important article.
TROV Company Profile
Trovagene, Inc. (TrovaGene), incorporated on September 21, 2009, is a molecular diagnostic company. The Firm focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. The Company’s primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. The Firm has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.